Another study showed that the newly identified ephrin B1/ErbB/PTPN13 signaling pathway [71] is implicated in the resistance to a monoclonal antibody against ERBB1 (cetuximab) in HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.